tiprankstipranks

Axsome Therapeutics price target lowered to $125 from $127 at Citi

Citi analyst David Hoang lowered the firm’s price target on Axsome Therapeutics to $125 from $127 and keeps a Buy rating on the shares following the Q1 report. Auvelity overcame seasonal headwinds to report $53.4M in revenue, a modest beat, with favorable script trends exiting the quarter and progress on payor contracting that may lead to better formulary coverage near-term, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue